atgl

Atglistatin is a highly effective, specific and competitive ATGL inhibitor with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, and no toxicity when the concentration up to 50 μM.

Y-320 is a new phenylpyrazoleanilide immunomodulator.

NG-497 is a selective, small molecule inhibitor of human adipose triglyceride lipase (ATGL) that targets the enzymatically active patatin-like structural domain of human ATGL.NG-497 binds ATGL in a hydrophobic lumen adjacent to the active site.NG-497 abrogates lipolysis in human adipocytes in a dose-dependent and reversible manner.NG-497 has been shown to be useful in cancer research. can be used in cancer research.

COP1-ATGL modulator 1 (86) is an orally active compound that targets the COP1-ATGL axis. It enhances ATGL protein expression, decreases ATGL ubiquitination and COP1 autoubiquitination, and notably reduces lipid accumulation in hepatocytes, effective in the nanomolar concentration [1].

Glucuronokinase (AtGlcAK), a GHMP-kinase family member, displays exclusive substrate specificity for D-glucuronic acid, evidenced by a K m of 0.7 mM. It catalyzes the transformation of D-glucuronic acid and ATP into D-glucuronic acid-1-phosphate and ADP [1].

TAT-GluA2 3Y acetate is an inhibitor of AMPA receptor endocytosis.Systemic administration of Tat-GluA2(3Y) during the induction phase of d-amphetamine blocked maintenance of behavioural sensitization and attenuated the maintenance of neurochemical sensitization of rat.

Epirubicin hydrochloride (Pharmorubicin) is an adriamycin derivative, a topoisomerase (Topo) inhibitor, and a Forkhead box protein p3 (Foxp3) inhibitor. Epirubicin hydrochloride has antitumor activity.

GRA Ex-25 (GRA-Ex-25) is an inhibitor of glucagon receptor.

Olumacostat glasaretil is a small molecule inhibitor of acetyl coenzyme A carboxylase (ACC). It has been used in trials studying the treatment of Acne Vulgaris.

Belinostat Glucuronide is the major metabolite of Belinostat. Belinostat is a novel histone deacetylase 3 selective inhibitor that protects β cells from cytokine-induced apoptosis.

TAT-GluN2BCTM is a membrane-permeable peptide that selectively targets active DAPK1 (Death-associated protein kinase 1) for lysosomal degradation, protecting neurons against oxidative stress and NMDAR-mediated excitotoxicity, making it valuable for neuroprotection research studies [1].

TAT-GluR23A Fusion Peptide is a bioactive peptide comprising the GluR23A sequence—residues 869 to 877 of GluR23Y with alanine replacing tyrosine—and an 11 amino acid cell-permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). It serves as an inactive control counterpart to the glutamate receptor endocytosis inhibitor GluR23Y, devoid of crucial phosphorylation sites.

TAT-GluR6-9c is a blocker of GluR6-PSD95 interaction. It inhibits JNK activation and c-Jun phosphorylation by regulating GluR6-mediated signaling pathways, thereby reducing Fas L expression and decreasing apoptosis. TAT-GluR6-9c is applicable in the study of cerebral ischemia and neuroprotection strategies.

Molidustatglucuronide (BAY-348) is the N-glucuronide metabolite of Molidustat. Primarily formed through glucuronidation, it is the sole metabolite of Molidustat present in human and animal plasma. Molidustat glucuronide is utilized in the study of Molidustat's metabolic pathways and pharmacokinetic properties.